Second Opinion November 1, 2024
That’s the question of the moment – and we explore it in-depth.
I co-wrote and researched this piece with health policy writer and former Politico journalist Megan Wilson.
Within the next decade, nearly half of Americans may qualify to take a GLP-1 drug like Ozempic or Wegovy — and, as demand rises, many employers are asking: How do we cover them?
As we all know, these medications aren’t cheap. Before drugmaker discounts, the price tag can be as much as $1,300 per dose. One study shows that GLP-1 drug costs become one of a company’s top five expenses once a plan begins covering them. Experts worry that even emerging generics will be too spendy for...
Today's Sponsors
Today's Sponsor